Coriolis Pharma expands its ATMP development facilities

The cell and gene therapy formulation R&D specialist will add a BSL2 facility, totaling Coriolis Pharma’s floor space to 7,800 m². The new labs will host the formulation development of ATMPs, cell culture activities, particle characterisation and identification, analytical ultracentrifugation and a lyophilisation development center for ATMPs.

Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced. Similar to mRNA vaccines and gene therapies, ATMPs either have a very short shelf life (hours to days) or require ultra-cold storage conditions. A tailored formulation development program mayremarkably improve this situation.